BioLife Solutions, Inc. (BLFS) Key Metrics
BLFS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.89B
- Enterprise value
- $1.78B
- P/E (TTM)
- 39.0
- Forward P/E
- 238.1
- PEG ratio
- 65.38
- Price / sales
- 17.7 10-yr median 11.0
- Price / book
- 4.4 10-yr median 3.6
- EV / EBITDA
- 343.6 10-yr median 218.3
- Dividend yield
- —
- Beta
- 1.82
BLFS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBLFS valuation Price multiples at each fiscal year-end price.
BLFS returns How much profit the business earns on the capital it uses.
BLFS per-share figures Results divided by the shares outstanding at year-end.
BLFS financial health Debt, liquidity and how easily interest is covered.
BLFS efficiency & capital use Working capital cycle and where the cash goes.
BLFS valuation history
BLFS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BLFS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BLFS cash returned to shareholders
BLFS price vs earnings per share
BLFS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.18B | $1.20B | $710.4M | $773.2M | $1.44B | $1.09B | $314.9M | $195.6M | $79.6M | $20.4M |
| Enterprise value | $1.11B | $1.12B | $700.1M | $754.2M | $1.39B | $1.01B | $309.8M | $164.9M | $72.9M | $24.6M |
| P/E ratio | — | — | — | — | — | 408.4 | — | 59.9 | — | — |
| Price / sales | 12.2 | 14.5 | 10.4 | 10.1 | 12.0 | 22.7 | 11.5 | 9.9 | 7.2 | 2.5 |
| Price / book | 3.2 | 3.4 | 2.1 | 2.1 | 3.0 | 5.3 | 3.8 | 13.4 | 7.9 | 6.4 |
| Price / free cash flow | — | 229.8 | — | — | — | 578.8 | 585.3 | 105.8 | 172.5 | — |
| Price / operating cash flow | 58.5 | 141.8 | — | — | — | 167.2 | 259.6 | 83.3 | 131.5 | — |
| EV / sales | 11.5 | 13.6 | 10.3 | 9.9 | 11.7 | 21.0 | 11.3 | 8.4 | 6.6 | 3.0 |
| EV / EBITDA | 306.5 | 732.0 | — | 130.1 | — | 581.8 | 120.7 | 41.2 | — | — |
| EV / free cash flow | — | 215.5 | — | — | — | 536.6 | 575.8 | 89.2 | 158.1 | — |
| Earnings yield | −1.0% | −1.7% | −9.6% | −18.1% | −0.6% | 0.2% | −0.5% | 1.7% | −3.2% | −33.8% |
| Free cash flow yield | 0.0% | 0.4% | −2.7% | −2.4% | −0.9% | 0.2% | 0.2% | 0.9% | 0.6% | −27.4% |
| Dividend yield | — | — | — | — | — | — | 0.0% | 0.2% | 0.1% | 0.5% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | 0.0% | 0.0% | 2.4% | 0.1% | 0.5% |
| Share price at fiscal year-end | $24.18 | $25.96 | $16.25 | $18.20 | $37.27 | $39.89 | $16.18 | $12.03 | $6.00 | $1.61 |
| Per share | ||||||||||
| Revenue per share | $1.98 | $1.79 | $1.56 | $1.79 | $3.09 | $1.76 | $1.41 | $1.21 | $0.83 | $0.65 |
| Earnings per share | −$0.25 | −$0.44 | −$1.56 | −$3.29 | −$0.23 | $0.10 | −$0.09 | $0.20 | −$0.19 | −$0.54 |
| Operating cash flow per share | $0.41 | $0.18 | −$0.29 | −$0.20 | −$0.13 | $0.24 | $0.06 | $0.14 | $0.05 | −$0.34 |
| Free cash flow per share | $0.01 | $0.11 | −$0.43 | −$0.44 | −$0.34 | $0.07 | $0.03 | $0.11 | $0.03 | −$0.44 |
| Cash per share | $1.83 | $2.27 | $1.01 | $1.48 | $1.81 | $3.31 | $0.33 | $1.89 | $0.50 | $0.11 |
| Book value per share | $7.64 | $7.57 | $7.72 | $8.57 | $12.42 | $7.52 | $4.27 | $0.90 | $0.76 | $0.25 |
| Tangible book value per share | $3.27 | $2.76 | $2.10 | $2.53 | $2.63 | $4.24 | $1.41 | $0.90 | $0.76 | −$0.06 |
| Dividends per share | — | — | — | — | — | — | $0.00 | $0.03 | $0.01 | $0.01 |
| Capex per share | $0.40 | $0.07 | $0.15 | $0.24 | $0.22 | $0.17 | $0.03 | $0.03 | $0.01 | $0.10 |
| Debt per share | $0.37 | $0.66 | $0.77 | $1.03 | $0.70 | $0.41 | $0.07 | — | $0.00 | $0.45 |
| Shares outstanding | 48.6M | 46.1M | 43.7M | 42.5M | 38.5M | 27.3M | 19.5M | 16.3M | 13.3M | 12.6M |
| Change in shares outstanding | +5.6% | +5.4% | +2.9% | +10.3% | +41.0% | +40.3% | +19.7% | +22.6% | +4.9% | +3.8% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −3.4% | −5.9% | −19.4% | −33.2% | −2.6% | 1.9% | −3.4% | 26.4% | −37.9% | −117.8% |
| Return on invested capital (ROIC) | −0.3% | −1.9% | −4.6% | −1.2% | −8.6% | −2.6% | −0.6% | — | −15.3% | −63.2% |
| Return on assets (ROA) | −3.0% | −5.0% | −15.8% | −27.8% | −2.3% | 1.6% | −2.4% | 11.3% | −25.1% | −67.7% |
| Return on tangible assets | −6.3% | −11.4% | −40.8% | −72.3% | −5.0% | 1.8% | −4.4% | 7.2% | −20.7% | −171.3% |
| Free cash flow margin | 0.4% | 6.3% | −27.8% | −24.8% | −11.1% | 3.9% | 2.0% | 9.4% | 4.2% | −67.9% |
| Income quality (OCF / net income) | — | — | — | — | — | 2.44 | — | 0.72 | — | — |
| Financial health | ||||||||||
| Total debt | $17.9M | $30.2M | $33.8M | $43.7M | $26.9M | $11.2M | $1.4M | — | $0 | $5.7M |
| Cash & short-term investments | $88.9M | $104.6M | $44.2M | $62.7M | $69.9M | $90.5M | $6.4M | $30.7M | $6.7M | $1.4M |
| Net debt | −$71.0M | −$74.4M | −$10.4M | −$19.0M | −$43.0M | −$79.3M | −$5.1M | −$30.7M | −$6.7M | $4.3M |
| Debt / equity | 0.05 | 0.09 | 0.10 | 0.12 | 0.06 | 0.05 | 0.02 | — | 0.00 | 1.80 |
| Debt / assets | 0.04 | 0.08 | 0.08 | 0.10 | 0.05 | 0.05 | 0.01 | — | 0.00 | 0.72 |
| Net debt / EBITDA | −19.70 | −48.57 | — | −3.28 | — | −45.68 | −1.98 | −7.66 | — | — |
| Current ratio | 5.94 | 4.54 | 2.86 | 3.11 | 2.95 | 7.37 | 3.15 | 19.37 | 6.56 | 4.08 |
| Quick ratio | 4.63 | 3.66 | 1.83 | 2.32 | 2.29 | 6.62 | 1.70 | 17.56 | 5.34 | 2.53 |
| Interest coverage | -0.4 | -9.9 | -10.7 | -8.6 | -63.2 | -185.1 | -44.0 | 732.4 | -5.6 | -15.2 |
| Working capital | $113.6M | $116.0M | $78.4M | $93.9M | $83.4M | $99.1M | $16.5M | $35.6M | $8.4M | $3.5M |
| Invested capital | $300.9M | $274.5M | $327.3M | $345.2M | $435.1M | $125.9M | $77.9M | −$16.0M | $3.4M | $7.4M |
| Tangible asset value | $159.0M | $127.0M | $91.8M | $107.4M | $101.2M | $115.7M | −$12.0M | $14.6M | $10.1M | −$748,120 |
| Net current asset value | $102.6M | $98.2M | $45.6M | $52.4M | $49.8M | $85.1M | −$25.2M | $6.7M | $7.9M | −$133,000 |
| Graham number | — | — | — | — | — | $4.06 | — | $2.02 | — | — |
| Graham net-net per share | $1.56 | $1.64 | $0.11 | $0.46 | $0.65 | $2.66 | −$1.71 | $0.24 | $0.48 | −$0.13 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | $0 | $436,000 | $106,250 | $106,000 |
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $4.2M | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | — | — | 13.3% | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 0.0% | 0.0% | 253.6% | 23.0% | — |
| Capex / revenue | 20.5% | 3.9% | 9.4% | 13.6% | 7.0% | 9.6% | 2.5% | 2.5% | 1.3% | 15.3% |
| Capex / operating cash flow | 97.9% | 38.3% | — | — | — | 71.1% | 55.6% | 21.3% | 23.8% | — |
| Capex / depreciation | 4.20 | 0.37 | 0.52 | 0.63 | 0.65 | 0.91 | 0.38 | 1.48 | 0.42 | 3.42 |
| Stock-based compensation / revenue | 23.9% | 37.6% | 46.6% | 33.2% | 11.7% | 12.4% | 11.1% | 7.7% | 11.5% | 9.4% |
| R&D / revenue | 7.9% | 9.6% | 8.1% | 19.4% | 9.9% | 14.0% | 15.1% | 6.6% | 10.8% | 24.7% |
| SG&A / revenue | 57.5% | 61.0% | 79.6% | 43.6% | 40.0% | 43.7% | 49.7% | 43.4% | 60.0% | 92.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 32.5 | 61.7 | 141.1 | 136.8 | 47.8 | 50.7 | 55.9 | 37.6 | 36.7 | 47.1 |
| Days of inventory on hand | 316.7 | 462.7 | 535.6 | 393.6 | 88.8 | 175.1 | 271.4 | 157.2 | 153.9 | 190.2 |
| Days payables outstanding | 27.1 | 67.1 | 152.5 | 188.6 | 41.4 | 52.3 | 71.2 | 41.4 | 59.8 | 92.1 |
| Cash conversion cycle (days) | 322.1 | 457.3 | 524.3 | 341.8 | 95.2 | 173.5 | 256.1 | 153.4 | 130.7 | 145.1 |
| Receivables turnover | 11.24 | 5.91 | 2.59 | 2.67 | 7.63 | 7.20 | 6.52 | 9.71 | 9.95 | 7.75 |
| Payables turnover | 13.48 | 5.44 | 2.39 | 1.94 | 8.82 | 6.97 | 5.13 | 8.81 | 6.10 | 3.96 |
| Inventory turnover | 1.15 | 0.79 | 0.68 | 0.93 | 4.11 | 2.08 | 1.35 | 2.32 | 2.37 | 1.92 |
| Asset turnover | 0.24 | 0.20 | 0.16 | 0.15 | 0.30 | 0.29 | 0.40 | 0.69 | 1.10 | 0.81 |
| Average receivables | $8.6M | $13.9M | $26.3M | $28.6M | $15.6M | $6.7M | $4.2M | $2.0M | $1.1M | $1.1M |
| Average payables | $2.5M | $5.3M | $11.2M | $15.2M | $9.3M | $3.4M | $1.9M | $705,500 | $700,860 | $870,046 |
| Average inventory | $29.6M | $36.2M | $39.2M | $31.6M | $20.0M | $11.4M | $7.3M | $2.7M | $1.8M | $1.8M |
| Intangibles / total assets | 52.4% | 55.5% | 59.6% | 57.0% | 68.0% | 38.1% | 59.8% | 0.0% | 0.0% | 49.4% |
Computed from BLFS's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BLFS valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 39.0 and the forward P/E is 238.1. BioLife Solutions earned a return on equity of −3.4% and a return on invested capital of −0.3% in fiscal 2025. It ended the year with $17.9 million of debt and $88.9 million in cash and short-term investments, a net cash position of $71.0 million. The share count rose 284.8% from 12.6M to 48.6M over 9 years.
See the BLFS income statement, the BLFS chart for price history, or the BLFS stock overview for the latest quote and news.
BLFS key metrics FAQ
What is BioLife Solutions's P/E ratio?
BioLife Solutions's trailing P/E ratio is 39.0 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 238.1. At the end of fiscal 2025 it was —.
What is BioLife Solutions's EV/EBITDA?
BioLife Solutions's enterprise value was 306.5 times EBITDA at the end of fiscal 2025 (enterprise value $1.1 billion, EBITDA $3.6 million); the current EV/EBITDA is 343.6.
What is BioLife Solutions's return on equity?
BioLife Solutions's return on equity (ROE) was −3.4% in fiscal 2025: net income of -$12.1 million on average shareholders' equity of $360.4 million.
What is BioLife Solutions's ROIC?
BioLife Solutions's return on invested capital was −0.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does BioLife Solutions have?
BioLife Solutions had total debt of $17.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is BioLife Solutions's free cash flow yield?
BioLife Solutions generated $0.4 million of free cash flow in fiscal 2025, a free cash flow yield of 0.0% on its market value at year-end ($1.2 billion).
What is BioLife Solutions's current ratio?
BioLife Solutions's current ratio was 5.94 at the end of fiscal 2025: current assets were 5.94 times current liabilities.